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SUMMARY. Background — In order to minimise retrospective recall in developing estimates of the prevalence of mental dis-
orders in the general population, we conducted a prospective study of a cohort of youth from Zurich, Switzerland. Method — A
20 year prospective study of a community-based cohort aged 19-20 from Zurich Switzerland. The sample was enriched by subjects
scoring high on the Symptom Checklist 90 R (Derogatis, 1977). A semi-structured diagnostic interview was administered by clin-
ically experienced psychologists and psychiatrists. The six interviews from 1979 to 1999 assessed diagnoses and sub-threshold
manifestations of major diagnostic categories (with the exception of schizophrenia) for the past twelve months, depending on the
current DSM versions (DSM-IH, DSM-HI R, DSM-IV). Additional information on symptoms and treatment were collected for the
years between the interviews. The reported prevalence rates are weighted for stratified sampling and cumulate the one-year rates
of the six interviews. Results —The cumulative weighted prevalence rates for any psychiatric disorder were 48.6% excluding, and
57.7% including tobacco dependence. In addition 29.2% and 21.8%, respectively manifested sub-diagnostic syndromes. Overall
there were no significant gender differences. The corresponding treatment prevalence rates were 22.4% and 31.1%, respectively
for the diagnostic subjects and 6.9% and 6.1 %, respectively for the sub-diagnostic groups. The total treatment prevalence rate was
37.2% of the population (males 30.0%, females 44.1%). Conclusions — Our findings reveal that psychiatric disorders are quite
common in the general population. When the spectra of mental disorders are considered, nearly three quarters of the general pop-
ulation will have manifested at least one of the mental disorders across their lifetime. Limitations — The data are based on a rel-
atively small sample; a single age cohort, and the study was conducted in Zurich, Switzerland. These study features may diminish
the generalisability of the findings.
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INTRODUCTION Switzerland. Because there were no standardised diag-
nostic interviews for mental and functional somatic dis-
The Zurich Cohort Study of Young Adults was orders at the study inception in 1978, a new diagnostic
designed to investigate the prevalence of mental disor- interview (SPIKE) was developed to embrace a wide
ders and symptoms and functional somatic syndromes in range of psychiatric syndromes and symptoms as well as
the general population of the canton of Zurich, functional somatic syndromes (Angst et al., 1984). Since
this time, there has been substantial development in diag-
nostic instrumentation including the Diagnostic
Interview Schedule (DIS) (Robins et al, 1981) and the
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classification systems during the past 20 years, with sev-
eral versions of the diagnostic criteria having been used
across the duration of the study (DSM-III1980, DSM-III
R 1987 and DSM-IV 1994). Diagnostic criteria changes
were incorporated into respective versions of the SPIKE
interview.
This paper reports the cumulative one-year prevalence
rates of mental disorders and sub-diagnostic (sub-thresh-
old) syndromes based on six interviews over a 20-year
period as a cohort of youth ages 19-20 progressed
through early adulthood. This age group is passing
through the prime period for onset and establishment of
major and minor mental disorders. The chosen methodol-
ogy is based on a number of unpublished pre-studies, of
which only two may be mentioned briefly.
PRE-STUDIES
The design of the Zurich Study was influenced by a
questionnaire study on recall, carried out in 1976 in 153
males and 61 females. 105 of 212 mailed questionnaires
(49%) were returned (Kaeser, 1979; Weber, 1979).
Recall was quite poor, with about one fourth of subjects
who had been examined for behavioural and/or psycho-
logical problems (documented in the school health
records) failing to recall the problems that they had
reported earlier. There was no difference in recall of
behavioural problems (truancy, running away, conflict
with teachers and parents, lying, stealing) versus psycho-
logical problems (depression, anxiety, sleep terrors).
In 1975 a random sample of 126 19-year old Swiss
men (recruited at the mandatory conscription, but exam-
ined in research groups under medical secrecy) were
given the Hopkins Symptoms Checklist (HSCL-58,
(Derogatis et al, 1974)) and the General Health
Questionnaire (GHQ) as a screening instrument
(Goldberg & Williams, 1988). Using the GHQ as a gold
standard, there was an overall agreement in 90 cases (16
positives and 74 negatives); 33 were false positive cases
and 3 false negative cases. We found an acceptable sen-
sitivity and specificity (84.2% and 69.2% respectively)
when using a HSCL cut-off of 1.75. On the basis of its
sensitivity we chose the SCL-90 R (Derogatis, 1977),
which was the extension of the HSCL-58, as a screening
instrument providing a clinical syndrome profile with 9
sub-scales.
As a consequence of these earlier studies, and in order
to minimise memory problems, the Zurich Study was
originally designed to study the development prospec-
tively every year. However, because annual follow-ups of
this cohort were beyond the scope of our resources, we
conducted six waves of follow-up across the 20-year fol-
low-up.
METHODOLOGY
1. Sample
The Zurich Study is comprised of a cohort of 4,547
subjects (2201 males; 2346 females) representative of the
canton of Zurich in Switzerland, who were assessed in
1978 with the Symptom Checklist 90-R (Derogatis, 1977)
and a questionnaire for socio-demographic data. The
study is based on a stratified sample with an over-repre-
sentation of risk cases. In order to increase the probabili-
ty of psychiatric syndromes, a sub-sample of 591 subjects
(292 males, 299 females) was selected for interview, with
two thirds consisting of high scorers (defined by the 85th
percentile or more of the SCL-90-R) and one third con-
sisting of a random sample of those with scores below the
85"1 percentile. The screening took place in 1978 at ages
19 (males) and 20 (females), the first and second inter-
views in 1979 and 1981, the third and fourth interviews
in 1986 and 1988, the fifth interview in 1993 and the
sixth in 1999. In 1980 a questionnaire, identical to the
screening was mailed (figure 1).
Across 20 years, 62.1% of the original sample contin-
ued to participate in the study and the following propor-
tions participated in specific numbers of interviews: 47%
in all 6 interviews; 63% in 5 interviews; 74% in 4 inter-
views; 82% in 3 interviews; and 91.4% in at least 2 inter-
views. Those who had dropped out did not differ signifi-
cantly from the 1999 participants regarding the risk group
at study entry and most demographic characteristics
(Eich etal, 2003).
2. Diagnostic Interview
The Structured Psychopathological Interview and
Rating of the Social Consequences for Epidemiology
(SPIKE) was administered in the participants homes by
psychiatric residents and clinical psychologists with
extensive clinical training (Angst & Dobler-Mikola,
1985). This interview schedule assesses a number of
somatic syndromes (including insomnia, headache, gas-
trointestinal, cardiovascular, respiratory, perimenstrual,
and sexual syndromes) and psychological syndromes
(including depression, hypomania, anxiety, phobia, obses-
sive-compulsive disorder, eating disorder, post-traumatic
stress disorder, substance abuse and suicidality).
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Figure 1. - Design of the Zurich cohort study.
Screening probes were based solely on the major phe-
nomenological features of each syndrome (e.g.,
depressed, sad mood, loss of joy/interests) and were
administered for each diagnostic category. Positive
endorsement of the screening probe was followed for
each syndrome first by queries about specific symptoms
and second about their duration, frequency and severity,
treatment history and impairment in work, social and
leisure activities. Visual analogue measures of subjective
distress and work impairment using a continuous scale
from 0 to 100, with 0 representing no distress (impair-
ment) and 100 indicating maximal distress (impairment)
were included in each diagnostic section of the interview.
Personal and family history of the syndromes were
assessed for all subjects, irrespective of endorsement of
the diagnostic screening question for each section.
Professional treatment was defined as consulting an M.D.
or a psychologist for the specific syndrome.
The inter-rater reliability of the SPIKE showed kappas
of 0.89 and 0.91 for the symptoms of depression and anx-
iety (GAD) and of 0.90 for the corresponding syndromal
diagnoses (Hochstrasser & Angst, 1996) (Wicki & Angst,
unpublished data). The validity of the SPIKE has also
been assessed by comparing physician ratings and med-
ical records to an administration of the SPIKE by anoth-
er clinician among 140 patients drawn from psychiatric
clinics or social-psychiatric services in the canton of
Zurich (Meier, 1985; Busslinger, 1984; Illes, 1981) and
from a local hospital (Pfortmiiller, 1983). The SPIKE rat-
ing of the diagnostic level of depression was found to
have high sensitivity and modest specificity (0.95 and
0.59, respectively, for major depression and 0.83 and
0.63, respectively, for minor depression). Likewise, the
SPIKE had good sensitivity for detecting sub-threshold
depression, anxiety and mania (i.e., respective kappas of
0.90, 0.83, 0.67).
3. Diagnostic Definitions
3.1. Threshold-Level
Classification of psychiatric disorders were made by
algorithms on the basis of DSM-HI criteria (GAD, panic
disorder), DSM-HI-R criteria (major depressive disorder,
phobias, obsessive-compulsive disorder (OCD)), and
DSM-IV criteria (post traumatic stress disorder, bipolar-II
disorder (BP-IT), and substance abuse/dependence). A diag-
nosis of bipolar-I disorder required hospital treatment for
mania rather than one week duration because none of the
subjects who met the latter criterion alone reported impair-
ment. Exclusion criteria were never applied in order to
investigate the associations between diagnostic categories.
3.2. Sub-threshold-Level
Depressive disorders Minor depression lasting two
weeks or more with 3-4 of 9 criterial symptoms of
depression. Recurrent brief depression: repeated (>11
episodes per year) spells of depression of brief duration
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(under two weeks) meeting symptom criteria of DSM-III-
R for major depressive episode. Anxiety Disorders
(Angst, 1998) Panic: repeated panic attacks (>1 attack)
over the past 12 months; Phobias: Phobic symptoms plus
avoidance behavior plus clinically significant distress;
Recurrent Brief Anxiety (RBA): repeated (>11 episodes
per year) spells of anxiety of brief duration (under two
weeks) meeting symptom criteria of DSM-III generalised
anxiety disorder (Angst & Wicki, 1992). Obsessive
Compulsive Syndrome (OCS) recurrent, persistent
obsessions or repetitive compulsions, interfering with
social or professional role functioning (Degonda et al.,
1993). Eating Disorders Binge Eating: at least four
binges over one year (Vollrath et al, 1992) Substance
Use Disorders Alcohol: regular drinking (i.e., > 4 days
per week; 4-6 drinks per occasion) without consequences
Tobacco: daily smoking without consequences or depen-
dence; Drugs: Cannabis use weekly over one year,
Cocain, Heroin, Hallucinogens) use four or more times
per week without social or personal consequences.
4. Statistical Analysis
Chi square tests and Kruskal-Wallis tests (Kruskal &
Wallis, 1952) were computed by SAS Version 8.2.
Prevalence rates and standard errors were computed by
Stata 8.2 adjusting for sample stratification. For each
interview the prevalence rates were computed for the past
12 months. Cumulative prevalence rates were then com-
puted across six interviews as the cohort progressed from
ages 20 to 40.
RESULTS
Social and Demographic Variables
The socio-demographic distribution of the sample
according to the original risk group and lifetime presence
or absence of a mental disorder was analysed. Those with
a disorder did not differ from controls with respect to
social class, parents' income, fathers' profession, non-
intact family, probands' education, and urbanisation (size
of home town).
Overall Cumulative Prevalence Rates
Estimates of lifetime cumulative prevalence of the
major diagnostic categories are presented in table I.
These rates are not mutually exclusive and therefore may
include the same individual in multiple categories. The
magnitude of mood disorders (24%), anxiety disorders
(26%), and substance abuse/dependence (24%) were
quite similar. There was a preponderance of women with
mood and anxiety disorders, and a comparable prepon-
derance of males with substance abuse/dependence. A
total cumulative prevalence rate of 48.6% was found for
all DSM diagnoses: mood and anxiety disorders, sub-
stance abuse/dependence and bulimia. There was no gen-
der difference in the aggregate estimate of mental disor-
ders. The total prevalence rates of aggregate sub-thresh-
old disorders was 29.2%, with a 1.3 greater aggregate rate
among females compared to males. The threshold and
Table I. - Sex-specific 20 year cumulative prevalence rates of major categories of mental disorders.
DISORDERS
MOOD DISORDERS
ANXIETY DISORDERS
SUBSTANCE ABUSE/
DEPENDENCE
Alcohol abuse/dependence
Drug
abuse/dependence
Tobacco dependence
TOTAL'
TOTAL2
THRESHOLD
Cumulative 1
Both
(95% C.I.)
24.2 (2.5)
(19.3-29.1)
26.3 (2.6)
(21.6-31.7)
23.7 (2.5)
(18.1-28.0)
17.9 (2.3)
(13.4-22.4)
8.0(1.6)
(4.9-11.2)
40.5 (3.3)
(34.0-46.9)
48.6(3.1)
(42.6-54.5)
57.7 (3.1)
(51.6-63.5
Prevalence
Males
(95% C.I.)
18.5 (3.2)
(12.2-24.8)
18.9 (3.2)
(13.4-26.0)
32.7 (4.1)
(24.7-40.7)
28.0 (3.9)
(21.0-36.2)
11.7(2.7)
(7.4-18.1)
45.0 (4.7)
(35.9-54.3)
48.9 (4.4)
(40.5-57.4)
58.1 (4.3)
(49.4-66.3)
Females
(95% C.I.)
29.8 (3.8)
(22.3-37.3)
33.6 (4.0)
(26.3-41.8)
13.7 (2.8)
(8.1-19.3)
8.0 (2.3)
(4.6-13.6)
4.5 (1.7)
(2.1-9.3)
36.0 (4.5)
(27.7-45.2)
48.2 (4.3)
(40.0-56.6)
57.3 (4.3)
(48.7-65.4)
F/M ratio
1.61
1.78
(p<.005)
0.42
0.28
0.38
0.80
.99
(p<-92)
.99
(p<.89)
SUB-THRESHOLD
Cumulative Prevalence
Both
(95% C.I.)
24.6 (2.6)
(19.8-30.1)
29.4 (2.8)
(24.2-37.2)
17.4 (2.3)
(13.4-22.4)
14.7 (2.2)
(10.9-19.5)
0.9 (0.4)
(0.3-2.4)
4.3 (1.2)
(2.4-7.4)
29.2 (2.8)
(24.0-35.1)
21.8(2.6)
(17.1-27.2)
Males
(95% C.I.)
23.1 (3.6)
(16.7-30.9)
26.9 (3.8)
(20.1-35.1)
18.0 (3.3)
(12.3-25.5)
18.7 (3.4)
(12.9-26.3)
1.4(0.9)
(0.4-4.9)
2.7 (1.3)
(1.1-6.7)
25.7 (3.8)
(18.9-33.9)
18.5 (3.4)
(12.7-26.1)
Females
(95% C.I.)
26.0(3.8)
(19.3-24.1)
31.8(4.1)
(24.5-40.3)
16.9 (3.2)
(11.5-24.1)
10.9 (2.7)
(6.6-17.4)
0.4 (0.2)
(0.2-0.9)
5.8 (2.1)
(2.8-11.4)
32.7(4.1)
(25.2-41.2)
25.0 (3.8)
(18.2-33.2)
F/M ratio
1.13
1.18
(p<.04)
0.94
0.58
0.29
2.15
1.28
(p<.14)
1.35
(P<.33)
1
 Total includes bulimia
2
 Total also includes bulimia and tobacco dependence
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Table II. - 20 year cumulative prevalence rates of major diagnostic categories of present study and selected recent studies.
DISORDERS
AUTHOR
Sample size
Age (years)
Criteria
Mood
Anxiety
Substance
abuse/dependence3)
TOTAL DISORDERS
ZURICH STUDY
Angst et al. (1984)
2599"
Cumulative
Prevalence
20-40
DSM-in/ m-R/ rv
Prevalence
(standard error)
24.2 (2.5)
26.3 (2.6)
23.7 (2.5)
48.6 (3.1)2»
NATIONAL
COMORBIDITY
SURVEY
Kesslerefa/. (1994)
8098
Lifetime
Prevalence
15-54
DSM-III-R
Prevalence
(standard error)
19.3 (0.7)
24.9 (0.8)
26.6(1.0)
47.3 (1.5)2
EDPS STUDY
MUNICH
WMH2000
NEMESIS STUDY
Wittchen et al. (1998) Bijl et al. (1998)
3021
Lifetime
Prevalance
14-24
DSM-IV
Prevalence
16.8
14.4
17.7
-
7076
Lifetime
Prevalence
18-64
DSM-HI-R
Prevalence
(standard error)
19.0 (0.5)
19.3 (0.5)
18.7 (0.5)
41.2(0.6)
GHS
Germany
Jacobi etal. (2004)
4181
Lifetime Prevalence
18-79
DSM-IV
Prevalence
(standard error)
18.6 (0.6)
9.9
" weighted
2)
 including sociopathy/ antisocial personality
" Substance abuse/dependence did not include nicotine
sub-threshold rates are mutually exclusive within major
diagnostic categories but not across categories.
Comparative Prevalence Estimates with Other
Community Surveys
Table II compares the lifetime prevalence rates of the
Zurich Cohort Study with those of other recent commu-
nity surveys that employed DSM-III-R or DSM-IV crite-
ria. Despite differences in diagnostic interviews, age
composition and time period prevalence estimates, the
rates of major diagnostic categories were similar between
the Zurich Study and the National Comorbidity Survey,
NCS (Kessler et al, 1994). The Nemesis study (The
Netherlands) (Bijl et al, 1998) and the EDPS study
(Munich) (Wittchen et al, 1998) tended to have slightly
lower rates. The high rate of mood disorders in the Zurich
Cohort Study is probably attributable to the prospective
design and lack of adherence to a duration criterion in the
probe for mood disorders.
Treatment Prevalence Rates
Nearly half (46.1%) of those with threshold level dis-
orders reported a history of treatment for that disorder.
About one fourth of those with sub-threshold-level disor-
ders reported lifetime treatment (i.e., 23.6%); in addition,
5.0% of subjects without any diagnosis were treated (fig-
ure 2). Approximately, one-fourth of subjects treated in
their lifetimes did not receive a DSM diagnosis. This
trend was far more frequent among women than among
men (respectively, 10.2% vs. 5.8%).
threshold
txwtad
M.I* (53.M)
subthrashoU
(M.0%)
m.tm at.tn
no diagnosis
Figure 2. - Proportion of treated subjects among cases of lifetime threshold, subthreshold and diagnosis-free cases. (Proportions
are higher if tobacco dependence/abuse is included (numbers in brackets).
Epidemiologia e Psichiatria Sociale, 14, 2, 2005
72
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S1121189X00006278
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 17:09:45, subject to the Cambridge Core terms of use, available at
Prevalence of mental disorders in the Zurich Cohort Study: a twenty year prospective study
Table III. -20 year cumulative treatment prevalence rates.
Disorder
MOOD
Anxiety
Substance
abuse/dependence
All disorders'
All disorders2
No diagnosis
M+F
(95% C.I.)
13.4(1.9)
(10.1-17.7)
9.3 (1.5)
(6.7-12.7)
3.7(1.0)
(2.2-6.2)
22.4 (2.4)
(18.1-27.4)
31.1 (2.7)
(26.0-36.6)
-
Threshold
Treatment Rates
M
(95% C.I.)
7.1 (2.0)
(4.1-12.2)
5.9(1.6)
(3.5-9.9)
4.5 (1.6)
(2.3-8.8)
18.5 (3.1)
(13.2-25.4)
25.6 (3.6)
(19.2-33.4)
-
F
(95% C.I.)
19.6 (3.2)
(14.0-26.6)
12.6 (2.5)
(8.4-18.4)
2.9 (1.2)
(1.2-6.6)
26.2 (3.5)
(19.8-33.7)
36.4 (4.0)
(28.9-44.5)
-
F/M ratio
2.76
(p<.03)
2.14
(p<.57)
0.64
(p<.44)
1.42
(p<.05)
1.42
(p-e-02)
-
M+F
(95% C.I.)
7.3 (1.5)
(4.9-10.8)
5.4(1.2)
(3.8-8.4)
.08 (.05)
(.02-.30)
6.9(1.5)
(4.5-10.6)
6.1 (1.5)
(3.7-9.7)
1.1 (0.6)
(0.3-3.3)
Subthreshold
Treatment Rates
M
(95% C.I.)
5.7(1.8)
(3.1-10.4)
3.7(1.3)
(1.9-7.3)
.08 (.08)
(.01-.60)
4.8 (1.8)
(2.3-9.7)
4.4(1.8)
(2.0-9.5)
1.0(0.9)
(0.2-5.7)
F
(95% C.I.)
8.9 (2.4)
(5.8-14.8)
7.0(2.1)
(3.8-12.3)
.08 (.08)
(.01-.50)
9.0 (2.5)
(5.2-15.2)
7.7 (2.4)
(4.2-13.8)
1.2 (0.9)
(0.3-5.0)
F/M ratio
1.56
(p<.38)
1.89
(p<-30)
1.00
(p<.98)
1.88
(P<36)
1.75
(p<-56)
1.2
(p<.68)
1
 including bulimia, but not tobacco use disorders
2
 including tobacco use disorders
The treatment prevalence rates of mood disorders
(13.4%), anxiety disorders (9.3%) and substance
abuse/dependence (3.7%) were highly variable. Whereas
55% of those subjects with mood disorders and 34% of
those with anxiety disorders had been treated, only 16%
of those with a substance use disorder had received treat-
ment. With the exception of substance abuse/dependence,
there was generally a marked preponderance of women
among treated subjects as shown by the high female to
male ratios in table III.
Prevalence of Single Diagnostic Categories (table IV)
Bipolar Disorder
DSM-criteria yielded very low prevalence rates of
bipolar disorders: 0.6% BP-1,0.9% BP-II and 1.2% hypo-
mania. Although no subjects met criteria for bipolar I
disorder at any of the six interviews, 4 subjects had been
hospitalised for the treatment of mania. These persons
failed to report impairment associated with their manic
symptoms. When sub-threshold definitions were includ-
ed, 11.0% of the population (5.3% with a narrow and
5.7% with a wide definition) met criteria for bipolar II
disorder (Angst et al., 2003). Sub-threshold minor bipo-
lar was found in 6.5%, pure hypomania in 4.0%, chronic
minor bipolar (i.e., cyclothymia) in 2.5%.
Depression
Major depressive disorder (DSM III-R) was found in
21.5% and dysthymic disorder in 2.8% of the population.
A female preponderance was present in MDD (OR=2.8;
CI= 1.2-6.6) but not in dysthymia. Most striking was the
finding that 89 of 190 cases (46.8%) with major depres-
sive episodes and 22 of 42 dysthymics (52.4%) also met
wide criteria for bipolar-II disorders. Excluding subjects
with at least two of seven criterial manic symptoms, only
11.4% met criteria for pure major depressive disorder.
Anxiety States
DSM-III panic disorder was found in 3.4% and sub-
threshold panic (i.e., repeated panic attacks or panic dis-
order) in 7.6% of the population. There was a strong
female preponderance in both groups. DSM-III gener-
alised anxiety disorder (GAD) (without exclusion crite-
ria) was found in 14.1 % of the population, and an
approximately equal proportion met criteria for sub-
threshold GAD.
Phobias
There were high prevalence rates of phobias (15.5%),
with variation in sex-specific rates according to phobic
subtypes. The greatest female-to-male ratio was found
for agoraphobia (3.7; OR=3.9; CI=1.2-12.8) and specific
phobia (3.1; OR=3.5; CI=1.5-8.2), with a lower and non-
significant ratio for social phobia (2.1; OR=2.2; n.s.).
Likewise, sub-threshold phobic states were even more
common than threshold level phobias.
OCD, OC-Syndromes and PTSD
The prevalence of OCD was 3.5% with a 3.2 fold
higher rate in females. Obsessive-compulsive syndromes
(excluding OCD) were found in 8.7% and were approxi-
mately equally common in men (9.9%) and women
(7.5%). Although post-traumatic stress disorder was
assessed at ages 35 and 40, no cases were found.
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Bulimia and Binge Eating
The prevalence of bulimia was 1.3%, occurring nearly
exclusively in females (2.3%). The same was true for
binge eating, which was identified in 9.9% of females
and 1.3% of males. The gender effects for bulimia
(OR=15.6; CI=2.7-89.8) and binge eating (OR=9.6;
CI=4.7-19.5) were both quite significant.
Substance Abuse and Dependence
The cumulative prevalence of alcohol dependence was
8.7%. Alcohol dependence occurred nearly exclusively
among males (14.5%), in whom there was a four-fold
greater frequency than among females (3.1%) (OR=0.2;
CI=0.1-0.4). A three-fold preponderance of males was
also found for illicit drug dependence (6.2% vs. 2.0%
among females; OR=0.3; n.s.). Slightly higher prevalence
rates were found for aggregate substance abuse. With the
exception of tranquillisers, males also had greater rates of
alcohol abuse or dependence (OR=0.2; CI=0.1-0.5) and
drug abuse or dependence (OR=0.4; CI=0.1-0.9).
Table IV. - 20 year cumulative prevalence of specific disorders in the Zurich cohort study.
Diagnostic level Threshold Sub-threshold
M+F
Prevalences
(95% C.I.)
Men
Prevalences
(95% C.I.)
Women
Prevalences
(95% C.I.)
M+F
Prevalences
(95% C.I.)
Men
Prevalences
(95% C.I.)
Women
Prevalences
(95% C.I.)
DISORDER MOOD DISORDERS
- Bipolar I
- Bipolar II
- Cyclothymia
- Hypomania
- Major/minor
depression1
- Dysthymia
ANXIETY STATES
Panic
GAD
PHOBIAS
Agoraphobia
Specific phobia
Social phobia
0.6 (0.4)
(0.1-2.6)
0.9 (0.6)
(0.2-3.4)
0.4 (0.4)
(0.0-3.0)
1.2 (0.6)
(0.4-3.3)
21.5 (2.4)
(17.1-26.5)
2.8 (0.8)
(1.6-4.8)
15.6(2.1)
(11.9-20.2)
3.4 (0.9)
(2.0-5.6)
14.1 (2.1)
(10.5-18.6)
15.5(2.1)
(11.8-20.1)
4.2(1.1)
(2.6-6.9)
10.7 (1.9)
(7.6-14.9)
7.6(1.4)
(5.2-10.9)
0.0 (0.0)
(0.0-0.6)
0.0
0.0
1.3 (0.9)
(0.3-5.0)
16.9(3.1)
(11.6-23.9)
2.6(1.0)
(1.3-5.3)
13.2 (2.8)
(8.6-19.8)
2.0 (0.9)
(0.8-4.9)
11.6(2.7)
(7.2-18.0)
9.1(2.3)
(5.5-14.8)
1.8 (0.9)
(0.7-4.9)
5.2 (1.8)
(2.6-10.0)
4.9(1.8)
(2.4-9.8)
1.0(0.9)
(0.2-5.3)
1.8(1.2)
(0.5-6.6)
0.9 (0.9)
(0.1-5.9)
1.2(0.9)
(0.3-4.9)
25.9 (3.6)
(19.5-33.6)
3.0(1.2)
(1.3-6.7)
17.9(3.1)
(12.5-24.8)
4.7(1.5)
(2.5-8.8)
16.5(3.1)
(11.3-23.5)
21.7 (3.4)
(15.7-29.1)
6.6 (1.9)
(3.7-11.5)
16.1 (3.2)
(10.8-23.3)
10.2 (2.3)
(6.5-15.5)
2.1 (0.9)
(0.9-4.7)
2.8 (1.0)
(1.4-5.5)
10.3 (1.9)
(7.1-14.7)
-
15.9 (2.2)
(2.0-20.7)
7.6(1.5)
(5.2-11.1)
12.0 (2.0)
(8.6-16.3)
22.8 (2.9)
(18.1-28.2)
4.4(1.2)
(2.5-7.5)
19.1 (2.4)
(14.7-24.3)
10.9(1.9)
(7.7-15.1)
0.3 (0.2)
(0.1-0.8)
3.4(1.5)
(1.4-8.0)
7.8 (2.3)
(4.4-13.6)
-
7.8(2.1)
(4.5-13.2)
1.7(0.4)
(1.1-2.6)
7.0(2.1)
(3.8-12.5)
17.4 (3.3)
(11.9-24.8)
1.7(0.9)
(0.6-4.8)
13.0 (3.0)
(8.2-20.1)
7.9(2.1)
(4.6-13.2)
3.7 (1.7)
(1.5-8.9)
2.2(1.2.)
(0.7-6.4)
12.8 (3.0)
(7.9-19.9)
-
23.7 (3.6)
(17.3-31.6)
13.4(2.8)
(8.8-20.0)
16.7 (3.2)
(11.4-23.9)
28.0 (3.9)
(20.9-36.3)
7.0 (2.2)
(3.7-12.8)
24.9 (3.7)
(18.3-33.0)
13.8 (3.0)
(8.9-20.8)
OBSESSIVE COMPULSIVE
DISORDER
EATING BULIMIA / BINGE
3.5(1.1)
(1.9-6.3)
1.3 (0.6)
(0.5-3.3)
1.7(0.9)
(0.6-4.8)
0.2 (0.1)
(0.0-0.6)
5.4 (1.9)
(2.6-10.5)
2.3 (1.2)
(0.8-6.4)
8.7 (1.6)
(6.0-12.4)
5.6(1.0)
(3.6-8.8)
9.9 (2.4)
(6.0-15.8)
1.3 (0.3)
(0.8-2.0)
7.5(2.1)
(4.3-12.7)
9.9 (2.5)
(6.0-16.0)
SUBSTANCE ABUSE
AND DEPENDENCE
Alcohol dependence
Alcohol abuse (excl)
Alcohol total
Illicit drugs abuse/dep
Tranquilliser dep.
Tranquilliser abuse
Tranquiliser total
Tobacco dependence
1
 Minor depression = subthreshold
23.1 (2.5)
(18.5-28.4)
8.7 (1.6)
9.2 (1.8)
17.9 (2.3)
(13.8-22.9)
4.1 (1.2)
(2.3-7.3)
1.2 (0.6)
(0.4-3.3)
2.4 (0.9)
(1.1-4.9)
3.6(1.1)
(2.0-6.4)
33.4 (2.9)
(28.1-39.2)
32.7(4.1)
(25.3-41.1)
(6.0-12.5)
(6.2-13.3)
28.0 (3.9)
(21.0-36.2)
6.2(2.1)
(3.2-11.9)
1.9(1.2)
(0.5-6.7)
0.6 (0.2)
(0.3-1.2)
2.5(1.3)
(0.9-6.6)
37.6 (4.2)
(29.8-46.1)
13.7 (2.8)
(9.0-20.3)
14.5 (3.0)
13.5 (3.0)
8.1 (2.2)
(4.6-13.6)
2.0(1.2)
(0.6-6.4)
0.5 (0.2)
(0.3-1.1)
4.1(0.2)
(1.8-9.1)
4.6(1.7)
(2.2-9.4)
29.4 (3.9)
(22.4-37.4)
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17.4 (2.3)
(13.4-22.4)
(9.6-21.4)
(8.6-20.5)
4.0(1.1)
(2.3-6.7)
-
14.7(2.1)
(11.0-19.3)
4.3(1.2)
(2.4-7.4)
14, 2, 2005
18.0 (3.3)
(12.3-25.5)
3.1 (1.2)
5.0(1.9)
-
5.5(1.8)
(2.9-10.2)
-
8.8 (2.4)
(5.0-14.8)
2.7(1.3)
(1.1-6.7)
16.9(3.2)
(11.5-24.1)
(1.4-6.7)
(2.3-10.3)
-
2.5 (1.2)
(0.9-6.4)
-
20.4 (3.4)
(14.5-27.9)
5.8(2.1)
(2.8-11.4)
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DISCUSSION
These findings demonstrate the high prevalence of
psychiatric disorders in the general population. Nearly
one in every two adults has experienced at least one
episode of a mood, anxiety, or substance use disorder that
has met contemporary diagnostic criteria. The lifetime
treatment prevalence rate of all mental disorders was
31% (men 26%, women 36%). Despite differences in the
methodological and sampling features across studies, the
morbidity estimates for aggregated disorders in the pre-
sent study are remarkably similar, but slightly higher than
those of other contemporary community studies (Jacobi
et al, 2004; Bijl et al, 1998; Kessler et al, 1994). The
lower rates of the EDPS study (Wittchen et al, 1998)
may be attributable to the young age of the cohort.
Our higher rates could be a consequence of the wide
probing by professionals for each interview section, to
the small sample size, or to repeated interviews, because
forgetting cannot be ignored in assessing lifetime-preva-
lence rates. The pilot study, which documented a 25%
loss of information by forgetting up to age 20, suggests
that the real lifetime prevalence may be higher than com-
monly reported.
The usual patterns of the female-to-male sex ratio
emerged in our data, with a moderate female preponder-
ance of mood and anxiety disorders and a four-fold
increased risk of substance use disorders among males.
The lack of sex differences in sub-threshold-level disor-
ders suggests that the sex difference may be attributed in
part to male-female differences in the severity and conse-
quences of mood and anxiety disorders rather than to dif-
ferences in symptoms themselves. This confirms our ear-
lier observation regarding differential male and female
thresholds for social phobia and panic (Merikangas et al,
1998).
An unresolved issue is the distinction between depres-
sion and bipolar disorder. Applying DSM-IV criteria for
hypomania, major depressive disorder (MDD) was
prevalent in 21.5%; in contrast, pure cases of MDD
shrank to 11.4% when the Zurich criterion of two of
seven hypomanic symptoms without time restriction was
applied, as shown in an earlier paper (Angst et al, 2003).
In 1984, on the basis of our data (Angst & Dobler-
Mikola, 1985) we concluded that there was a continuum
from normal to pathological expression of depression,
compatible with the view of Kessler (2002). Similar find-
ings have emerged for other manifestations as well, and
we have systematically examined the threshold validity
for all of the major anxiety disorders, bipolar disorder,
and phobic disorders for which sub-threshold definitions
have been developed (Angst F. et al, 2002; Angst &
Merikangas, 2001; Angst, 1998; Angst & Merikangas,
1997; Angst et al, 1997; Merikangas & Angst, 1994;
Degonda et al, 1993; Angst & Wicki, 1992; Vollrath et
al, 1992).
LIMITATIONS
The limitations of this study include: differences in
diagnostic information available across waves, since the
clinical interview was expanded over time to capture the
evolution of more extensive diagnostic systems; the
increasing attrition rate across the 20 years of the study;
and the relatively small sample size of this cohort and
limited generalisability to other cohorts.
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